Drug Profile
Research programme: 14-3-3 inhibitors - UniSA Ventures
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator University of South Australia
- Developer UniSA Ventures; University of South Australia
- Class Small molecules
- Mechanism of Action 14-3-3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Wounds
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Wounds in Australia
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in Australia (PO)
- 04 Aug 2016 Research programme: 14-3-3 inhibitors - UniSA Ventures is available for licensing - http://www.itek.com.au/portfolio/health/item/14-3-3-inhibition-to-accelerate-wound-healing.html